Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): Results of phase III AXIS trial.

@article{Rini2011AxitinibVS,
  title={Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): Results of phase III AXIS trial.},
  author={Brian I. Rini and Bernard Escudier and Piotr Tomczak and Andrey Dmitrievich Kaprin and Thomas E. Hutson and Cezary A. Szczylik and Jamal Christo Tarazi and Brad Rosbrook and Sinil Kim and Robert J Motzer},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 15_suppl},
  pages={4503}
}
4503 Background: Axitinib is an oral, potent, and selective inhibitor of VEGF receptors 1, 2, and 3. This randomized, open-label, phase III trial compared the efficacy and safety of axitinib versus (vs) sorafenib as second-line therapy for mRCC. METHODS Eligible patients had clear-cell mRCC; measurable, RECIST-defined progressive disease after 1 prior first-line systemic therapy with a sunitinib-, bevacizumab-, temsirolimus-, or cytokine-based regimen; and Eastern Cooperative Oncology Group… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 44 extracted citations

Review on targeted treatment of patients with advanced-stage renal cell carcinoma: a medical oncologist's perspective.

Asian Pacific journal of cancer prevention : APJCP • 2013
View 4 Excerpts
Highly Influenced

Combining antiangiogenics to overcome resistance: rationale and clinical experience.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2012
View 4 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…